Depression is common, costly, debilitating, and associated with increased risk of suicide. It is
one of the leading global public health problems. Although existing available …

Replicated international studies have underscored the human and societal costs associated
with major depressive disorder. Despite the proven efficacy of monoamine-based …

Background In treatment-resistant depression, commonly defined as a lack of response to
two or more consecutive treatments during the current depressive episode, the percentage …

Objectives: To provide advice and guidance regarding the management of mood disorders,
derived from scientific evidence and supplemented by expert clinical consensus to formulate …

The potential therapeutic use of some Cannabis sativa plant compounds has been attracting
great interest, especially for managing neuropsychiatric disorders due to the relative lack of …

Psychiatric disorders are highly prevalent, often devastating diseases that negatively impact
the lives of millions of people worldwide. Although their etiological and diagnostic …

Psychiatric disorders encompass complex aberrations of cognition and affect and are
among the most debilitating and poorly understood of any medical condition. Current …

Importance Whether ketamine is as effective as electroconvulsive therapy (ECT) among
patients with major depressive episode remains unknown. Objective To systematically …

Ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist first developed as an
anesthetic, has shown significant promise as a medication with rapid antidepressant …

Ketamine has rapid yet often transient antidepressant effects in patients with treatment-
resistant depression. Different strategies have been proposed to prolong these effects …